Professor of Medicine, Massachusetts General Hospital
Internal Medicine
Dr. Bruce A. Chabner, MD
|
|
Give Review
Bruce Chabner works in the field of Internal Medicine. He attended Harvard Medical School. Harvard Medical School is a one of the best medicals schools. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. He has 3 awards "Fellow (FASCO)", "Elected Member" and "Whos Who in Medicine and Healthcare". Bruce A. Chabner, MD is a published physician as well. He has 81 publications published. The latest was: A Roadmap for a New Academic Pathway for Global Radiation Oncology. He is registered with Medicare.
Publications
- Improving Prospects for Targeting RAS.
- A Roadmap for a New Academic Pathway for Global Radiation Oncology.
- Structural Approaches to Cancer Drug Development.
- Patient navigation based on predictive modeling decreases no-show rates in Cancer care.
- Defining a New Role for the National Cancer Institute Cooperative Groups: More Science, Fewer Trials.
- Addressing the Growing Cancer Burden in the Wake of the AIDS Epidemic in Botswana: The BOTSOGO Collaborative Partnership.
- Pharmacodynamic biomarkers: falling short of the mark?
- Approval After Phase I: Ceritinib Runs the Three-Minute Mile.
- Effective double whammy targets DNA synthesis in Leukemia.
- The Impact of a Culturally Tailored Patient Navigator Program on Cervical Cancer Prevention in Latina Women.
- Resolution: refresh, recharge, renew.
- ERBB2 inhibition and heart failure.
- Patient Navigation for Underserved Patients Diagnosed with Breast Cancer.
- Drug Shortages - A Critical Challenge for the Generic-Drug Market.
- It Is Time to Include Patients With Brain Tumors in Phase I Trials in Oncology.
- FLT3 Inhibition as Therapy in Acute Myeloid Leukemia: A Record of Trials and Tribulations.
- Early accelerated approval for highly targeted Cancer drugs.
- Patient perspectives of clinical care and patient navigation in follow-up of abnormal mammography.
- The oncologist chinese edition: a global mission, a unifying bond.
- Self-plagiarism.
- Reflections on the knife edge.
- Patient navigator programs, Cancer disparities, and the patient protection and affordable care act.
- New results will change the paradigm for phase I trials and drug approval.
- Academia-pharma intersect: providing a broader perspective on drug development synergies between academia and industry.
- About Eli.
- New trends and novel treatment for hepatoCellular carcinoma: a global perspective.
- Mysterious metformin.
- Medical interpreter knowledge of Cancer and Cancer clinical trials.
- Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
- Ghost writers in the sky.
- The National Cancer Institute and its Director: worthy of our full support.
- Dr. Joseph R. Bertino: a reflection.
- One in five Cancer clinical trials is published: a terrible symptom--what's the diagnosis?
- Preserving the sacred bond: an audit must be performed.
- Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell Lymphoma with analysis of germinal center and post-germinal center biomarkers.
- Usefulness of cardiac resynchronization therapy in the management of Doxorubicin-induced cardiomyopathy.
- Smoke, then fire: lung Cancer screening studies under further scrutiny.
- Conflict of interest: in the eye of the beholder?
- RNA-Directed Therapy: The Next Step in the miRNA Revolution.
- Trends in the use and role of biomarkers in phase I oncology trials.
- Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other ...
- Orange alert for oncologists.
- The FDA in 2006: reasons for optimism.
- Editors and authors: a sacred trust.
- Teams: communication in multidisciplinary care.
- Direct-to-consumer advertising in oncology.
- Laughter: the best medicine?
- Learning to cope: how far is too close?
- Breast Cancer: a tale of two centuries: with implications for understanding Cancer metastasis and Cancer stem cell biology.
- Fear of death.
- Trends in the risks and benefits to patients with Cancer participating in phase 1 clinical trials.
- Beyond fast track for drug approvals.
- Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.
- Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate Cancer.
- Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in Colorectal cancer.
- Cancer as metaphor.
- The miracle of Iressa.
- CME: the "third phase" of a doctor's education.
- Help me help you: support groups in Cancer therapy.
- The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision.
- Cancer therapy and survivorship.
- A tribute to Paul Calabresi: the man and the Matterhorn.
- Breaking bad news: a patient's perspective.
- Trust violated: analgesics for addicts.
- The dilemma of drug development and approval.
- Living as a Cancer surpriser: a doctor tells his story.
- The Kenneth B. Schwartz Center at Massachusetts General Hospital hematology-oncology department: hope for the homeless.
- Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women.
- Dose-adjusted EPOCH chemotherapy for untreated large B-cell Lymphomas: a pharmacodynamic approach with high efficacy.
- The role of rituximab and chemotherapy in aggressive B-cell Lymphoma: a preliminary report of dose-adjusted EPOCH-R.
- Pity the poor consumer.
- Faith, identity, and Leukemia: when blood products are not an option.
- When does the responsibility of our care end: bereavement.
- Cytotoxic agents in the era of molecular targets and genomics.
- Virtual connections: Internet health care.
- Choosing chemotherapy for lung Cancer based on cost: not yet.
- Between parent and child: negotiating Cancer treatment in adolescents.
- The trust factor.
- Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer.
- Announcing a new section: global health and Cancer.
Schools
Harvard Medical School
Peter Bent Brigham
Yale University
National Institute Health
Procedures Preformed
- Thoracentesis
Conditions Treated
- Anemia
- Chronic Myeloid Leukemia (CML)
- Colorectal Cancer
- Leukocytosis
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Internal Medicine
Accepted Insurances
Awards
- Fellow (FASCO)
- Elected Member
- Whos Who in Medicine and Healthcare
Education
-
Yale-New Haven Hospital -
Brigham and Women's Hospital -
Harvard Medical School
Hospital
-
Massachusetts General Hospital
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1467443176 |
| Last Name Of The Provider | CHABNER |
| First Name Of The Provider | BRUCE |
| View All |
Similar Doctors
|
|
Dr. Robert J. Friedlander Jr., MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pamela D. Vohra-Khullar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard N. Winickoff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karen H. Antman, MD
This Doctor is OpenDoctor Recommended.
|